H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on BiomX (PHGE) today and set a price target of $20.00. The company’s shares closed last Tuesday at $6.51.
According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 45.3% and a 68.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.
BiomX has an analyst consensus of Moderate Buy, with a price target consensus of $20.00, implying a 166.7% upside from current levels. In a report released today, Chardan Capital also reiterated a Buy rating on the stock with a $28.00 price target.
See today’s analyst top recommended stocks >>
BiomX’s market cap is currently $154.6M and has a P/E ratio of -1.50. The company has a Price to Book ratio of 2.45.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BiomX Ltd engages in developing bacteriophage-based therapies for the treatment and prevention of diseases stemming from dysbiosis of the microbiome. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.